Compare TPB & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TPB | ANIP |
|---|---|---|
| Founded | 1988 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Tobacco | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | 2015 | 1999 |
| Metric | TPB | ANIP |
|---|---|---|
| Price | $87.74 | $82.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $115.00 | $110.00 |
| AVG Volume (30 Days) | ★ 465.9K | 293.3K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.39% | N/A |
| EPS Growth | 45.33 | ★ 419.23 |
| EPS | ★ 3.11 | 1.28 |
| Revenue | ★ $463,062,000.00 | $206,547,000.00 |
| Revenue This Year | $13.68 | $21.01 |
| Revenue Next Year | $11.32 | $17.59 |
| P/E Ratio | ★ $28.31 | $65.45 |
| Revenue Growth | ★ 28.39 | 2.47 |
| 52 Week Low | $65.80 | $62.61 |
| 52 Week High | $146.90 | $99.50 |
| Indicator | TPB | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 55.04 | 48.53 |
| Support Level | $83.96 | $77.16 |
| Resistance Level | $93.44 | $83.66 |
| Average True Range (ATR) | 4.28 | 2.64 |
| MACD | 0.61 | -0.08 |
| Stochastic Oscillator | 83.69 | 39.80 |
Turning Point Brands Inc operates as a manufacturer, marketer, and provider of consumer products that include Other Tobacco Products (OTP) in the U.S. The company offers a wide variety across the OTP spectrum, including moist snuff tobacco (MST), loose-leaf chewing tobacco, premium cigarette papers, make- your-own (MYO) cigar wraps, cigars, liquid vapor products, and tobacco vaporizer products. It operates in two segments, namely Zig-Zag products and Stoker's products segment. The company generates maximum revenue from the Zig-Zag products segment.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.